BioMarin Pharmaceutical Inc (NASDAQ: BMRN) is a biotechnology company that develops and commercializes enzyme replacement therapies and other treatments for rare genetic diseases. Revenue is generated through product sales of approved therapies to patients, hospitals, and specialty distributors, with pricing reflecting the orphan-drug market where small patient populations support high per-unit treatment costs. The filing excerpts from the 10-K filed 2026-02-26 (accession 000104847726000004) do not provide sufficient segment revenue breakdowns, competitor names, geographic revenue splits, customer concentration data, or leadership details to support further specifics. All unsupported facts have been omitted per source-grounding rules.

Revenue model

Product sales of approved rare-disease therapies. Orphan-drug pricing model with high per-unit costs reflecting small patient populations. Specific revenue figures are not supported by the provided filing excerpts.

Products and services

Enzyme replacement therapies and treatments for rare genetic diseases. Specific product names are not supported by the provided filing excerpts.

Customers and end markets

Patients with rare genetic diseases, hospitals, and specialty distributors. Specific customer concentration or end-market data is not supported by the provided filing excerpts.

Value-chain role

Biopharmaceutical developer and commercial-stage manufacturer of rare-disease treatments.

Geographic exposure

Not supported by the provided filing excerpts.

Source: SEC 10-K, filed 2026-02-26

Industry: Pharmaceutical Preparations Peers: Alnylam Pharmaceuticals Inc Sarepta Therapeutics Inc Biogen Inc Biohaven Pharmaceutical Holding Co Ltd. Incyte Corp Moderna Inc Neurocrine Biosciences Inc Seagen Inc. Vertex Pharmaceuticals Inc